Duphaston: Progesterone Support for Hormonal Balance
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $3.21 | $64.26 (0%) | 🛒 Add to cart |
| 30 | $2.81 | $96.39 $84.34 (13%) | 🛒 Add to cart |
| 60 | $2.31 | $192.78 $138.56 (28%) | 🛒 Add to cart |
| 90 | $2.18 | $289.17 $195.79 (32%) | 🛒 Add to cart |
| 120 | $2.01 | $385.56 $240.98 (38%) | 🛒 Add to cart |
| 180 | $1.95 | $578.34 $351.42 (39%) | 🛒 Add to cart |
| 270 | $1.88 | $867.51 $507.05 (42%) | 🛒 Add to cart |
| 360 | $1.81
Best per pill | $1156.68 $650.63 (44%) | 🛒 Add to cart |
Duphaston (dydrogesterone) is a progestogen medication specifically engineered to mimic the effects of natural progesterone in the body. It is widely prescribed to address a range of conditions linked to progesterone deficiency or hormonal imbalance. As a synthetic hormone with a molecular structure closely resembling that of endogenous progesterone, it offers targeted action on the endometrium with a minimized impact on other bodily systems. Its primary therapeutic value lies in its ability to provide luteal phase support, regulate menstrual cycles, and maintain early pregnancy in cases of documented insufficiency. Clinicians favor it for its favorable safety profile and selective progestogenic activity, making it a cornerstone in gynecological and reproductive medicine.
Features
- Contains dydrogesterone, a retroprogesterone with high oral bioavailability
- Exhibits high selectivity for progesterone receptors
- Does not possess androgenic, estrogenic, glucocorticoid, or anabolic activity
- Provides predictable and consistent endometrial transformation
- Available in 10 mg tablet form for precise dosing
- Manufactured under strict pharmaceutical quality control standards
Benefits
- Effectively supports the luteal phase in assisted reproductive technology cycles, improving implantation rates
- Regulates irregular menstrual cycles by inducing predictable secretory transformation of the endometrium
- Reduces the risk of endometrial hyperplasia in women receiving estrogen replacement therapy
- Helps manage endometriosis-associated pain when used appropriately
- Provides essential hormonal support in cases of threatened or habitual abortion due to corpus luteum insufficiency
- Minimizes common progestogenic side effects such as weight gain and androgenic symptoms due to its selective action
Common use
Duphaston is primarily indicated for the treatment of disorders related to progesterone deficiency. Its most frequent applications include luteal phase support in infertility treatments, particularly in vitro fertilization cycles. It is prescribed for the management of dysfunctional uterine bleeding, where it helps establish regular withdrawal bleeding and prevents endometrial buildup. For women experiencing painful menstruation (dysmenorrhea) due to hormonal imbalance, Duphaston can provide significant symptomatic relief. It serves as the progestogenic component in hormone replacement therapy for postmenopausal women with an intact uterus, protecting against estrogen-induced endometrial hyperplasia. Additionally, it is used in the treatment of endometriosis, premenstrual syndrome, and secondary amenorrhea. In obstetric practice, it is employed to support early pregnancy in cases of documented luteal phase defect or history of recurrent pregnancy loss.
Dosage and direction
Dosage varies significantly based on the indication and individual patient response. For endometriosis, the typical regimen is 10 mg two or three times daily from day 5 to day 25 of the menstrual cycle. In infertility treatment for luteal phase support, 10 mg twice daily is typically initiated after ovulation and continued through the first trimester if pregnancy occurs. For dysfunctional bleeding, 10 mg twice daily is administered for 5-7 days to stop acute bleeding, followed by cyclic therapy (day 11-25) for 3-6 cycles. In hormone replacement therapy, it is prescribed at 10 mg daily for the last 12-14 days of each estrogen cycle. Tablets should be swallowed whole with water, with or without food, though consistent administration with meals may improve gastrointestinal tolerance. Duration of treatment ranges from several months to years depending on the condition being treated and clinical response.
Precautions
Before initiating Duphaston therapy, a thorough medical evaluation should be conducted, including a detailed personal and family history. Patients with a history of depression should be closely monitored, as progestogens may exacerbate mood disorders. Those with pre-existing renal or hepatic impairment require careful dosage consideration and potential monitoring of liver function. While Duphaston has minimal impact on carbohydrate metabolism, diabetic patients should be observed for possible changes in glucose tolerance. The medication does not provide contraceptive protection; patients should be advised to use non-hormonal contraception if pregnancy is not desired. Women who become pregnant during treatment should continue under close medical supervision. Unexpected bleeding during treatment warrants medical investigation to rule out pathological conditions.
Contraindications
Duphaston is contraindicated in patients with known hypersensitivity to dydrogesterone or any excipients in the formulation. It should not be used in individuals with a history of or current thromboembolic disorders, including deep vein thrombosis, pulmonary embolism, or cerebrovascular accident. Patients with known or suspected progesterone-dependent neoplasms, such as meningioma, should avoid this medication. Those with severe hepatic dysfunction or liver tumors (whether benign or malignant) are not candidates for treatment. Undiagnosed vaginal bleeding requires thorough investigation before initiation of therapy. The medication is contraindicated in cases of missed abortion or ectopic pregnancy.
Possible side effect
The majority of patients tolerate Duphaston well, with side effects typically being mild and transient. Commonly reported adverse reactions include nausea, headache, breast tenderness, and mild abdominal discomfort. Some women may experience breakthrough bleeding, particularly during the first few cycles of treatment. Less frequently reported effects include dizziness, fatigue, and skin reactions such as pruritus or rash. Mood changes, including irritability or depression, have been documented in a small percentage of users. Significant weight gain is uncommon due to the drug’s lack of androgenic activity. In rare instances, hypersensitivity reactions, including angioedema, may occur. Hepatic enzyme elevations have been reported but are typically reversible upon discontinuation.
Drug interaction
Duphaston is primarily metabolized by the cytochrome P450 3A4 system in the liver. Concomitant use with potent CYP3A4 inducers such as rifampicin, carbamazepine, phenytoin, or St. John’s Wort may reduce dydrogesterone concentrations and therapeutic efficacy. Conversely, strong CYP3A4 inhibitors like ketoconazole, ritonavir, or clarithromycin may increase plasma levels of dydrogesterone. While Duphaston has minimal effect on the metabolism of other drugs, caution is advised when co-administering with other hormonal therapies. The medication does not appear to significantly interfere with the efficacy of oral anticoagulants, though monitoring is recommended when initiating combined therapy.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Doubling the dose to make up for a missed tablet is not recommended. Consistent timing is particularly important when Duphaston is used for cycle regulation or luteal phase support. Patients should maintain a dosing diary or use reminder systems to enhance adherence, especially during critical treatment phases such as fertility cycles. If multiple doses are missed or uncertainty exists about how to proceed, patients should consult their healthcare provider for specific guidance.
Overdose
Acute overdose with Duphaston is unlikely to produce life-threatening symptoms due to its favorable safety profile. No specific antidote exists for dydrogesterone overdose. Potential manifestations may include nausea, vomiting, dizziness, or drowsiness. In cases of significant ingestion, gastric lavage may be considered if performed shortly after ingestion. Symptomatic and supportive care should be provided based on clinical presentation. Given the drug’s hormonal nature, menstrual irregularities might occur following significant overdose. Patients should be monitored for possible withdrawal bleeding. Medical attention should be sought for guidance, though hospitalization is rarely required.
Storage
Duphaston tablets should be stored in their original packaging at room temperature (15-30°C or 59-86°F), protected from light and moisture. The medication should be kept out of reach of children and pets. Tablets should not be transferred to alternative containers that lack proper labeling and protection from environmental factors. Do not use tablets beyond the expiration date printed on the packaging. Proper disposal of unused medication is recommended through take-back programs or following specific local guidelines for pharmaceutical waste, avoiding flushing down toilets or drainage systems.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual treatment decisions must be made by qualified healthcare professionals based on comprehensive patient assessment. The prescribing physician should be consulted for specific dosage recommendations and treatment duration. Patients should not alter their dosage or discontinue medication without medical supervision. While every effort has been made to ensure accuracy, pharmaceutical information may change over time with ongoing research and clinical experience.
Reviews
Clinical studies and patient reports consistently demonstrate Duphaston’s effectiveness in managing progesterone deficiency conditions. In reproductive medicine, it shows excellent results in supporting luteal phase function, with pregnancy rates comparable to natural progesterone preparations but with improved tolerability. Patients appreciate the minimal side effect profile compared to other progestogens, particularly the absence of significant androgenic effects. Many women report improved cycle regularity and reduced menstrual symptoms within the first few treatment cycles. In menopausal hormone therapy, it effectively protects the endometrium while causing fewer systemic effects than other progestogens. The majority of prescribing physicians consider it a valuable option in their therapeutic arsenal for hormonal disorders.